Quantum BioPharma Advances MS Treatment with New IND Agreement

Quantum Biopharma ( (TSE:QNTM) ) has issued an update.

On May 20, 2025, Quantum BioPharma Ltd. announced an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for Lucid-21-302, a novel treatment for multiple sclerosis. This agreement marks a significant step towards initiating a Phase 2 trial, potentially enhancing Quantum BioPharma’s position in the biopharmaceutical industry by advancing their innovative treatment pipeline. The successful development of Lucid-21-302 could have important implications for stakeholders, offering a new therapeutic option for MS patients.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is actively engaged in research and development through its subsidiary, Lucid Psycheceuticals Inc., particularly with its lead compound Lucid-MS, which targets multiple sclerosis. Quantum BioPharma also holds strategic investments and retains a significant stake in Celly Nutrition Corp., which markets an OTC product called unbuzzd.

Average Trading Volume: 8,813

Technical Sentiment Signal: Sell

Current Market Cap: C$32.98M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.